ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 954

Secukinumab, a Monoclonal Antibody to Interleukin-17A, Provides Significant and Sustained Inhibition of Joint Structural Damage in Active Psoriatic Arthritis Regardless of Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Désirée van der Heijde1, Robert B. M. Landewé2, Philip J. Mease3, Iain B. McInnes4, Philip G. Conaghan5, Luminita Pricop6, Gregory Ligozio7, Hanno Richards8 and Shephard Mpofu9, 1Leiden University Medical Center, Leiden, Netherlands, 2Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, 3Rheumatology Research, Swedish Medical Center, Seattle, WA, 4Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 5NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 6Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, 9Novartis Pharma AG, Basel, Switzerland

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: joint damage, monoclonal antibodies, Psoriatic arthritis, radiography and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis II - Novel Treatments Psoriatic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Approximately two-thirds of patients (pts) with psoriatic arthritis (PsA) experience progressive joint damage associated with varying degrees of disability. Here we present the 1-year effect of IL-17A inhibition with secukinumab on radiographic progression in pts with active PsA enrolled in a 2-year, multicenter, randomized, double-blind, placebo (PBO)-controlled, phase 3 trial (FUTURE 1; NCT01392326).

Methods

606 adults with moderate to severe PsA were randomized to PBO or one of two secukinumab treatment arms: secukinumab 10 mg/kg i.v. followed by 75 mg s.c. (10 IV→75 SC) or 150 mg s.c. (10 IV→150 SC). All pts were assessed for joint response at Week (Wk) 16 (based on ≥ 20% improvement in tender and swollen joint counts). PBO-treated pts were re-randomized to secukinumab 75 or 150 mg s.c. at Wk 16 (non-responders) or Wk 24 (responders). The van der Heijde total modified Sharp scores (mTSS), and erosion and joint space narrowing (JSN) scores were determined at baseline, Wks 16/24 (depending on response) and Wk 52. The effect of secukinumab on radiographic progression from baseline to Wk 24 was evaluated using a non-parametric ANCOVA model, with linear extrapolation for pts who had x-ray assessments at Wk 16. Exploratory analyses assessed the proportion of pts with no structural progression (defined as change from baseline in mTSS ≤ 0.5) and maintenance of this effect over time.

Results

The changes from baseline in mTSS, erosion and JSN scores demonstrated that secukinumab-treated pts had significantly less progression from baseline to Wk 24 compared with PBO-treated pts, regardless of whether pts had received prior therapy with a TNF inhibitor, were on secukinumab monotherapy, or were receiving concomitant methotrexate (MTX; Table). Inhibition of joint structural damage was sustained with secukinumab through Wk 52. Analysis of PBO pts who switched to secukinumab showed a greater mean change from baseline in mTSS for the PBO group from baseline to Wk 24 (mean increase of 0.48) vs. the period from Wk 24 to Wk 52 when pts had been switched to secukinumab (mean decrease of –0.03), providing additional support for efficacy. Analyses of pts who had x-rays at both Wk 16/24 and 52 showed that the proportion of pts who experienced no progression from randomization to Wk 24 vs. the period from Wk 24 to Wk 52 was consistently high in the secukinumab groups: 92.3% vs. 85.8%, respectively, for 10 IV→75 SC and 82.3% vs. 85.7% for 10 IV→150 SC. In pts initially randomized to PBO, 75.7% had no progression from randomization to Wk 24 and this increased to 86.8% for the period from Wk 24 to Wk 52 following active treatment with secukinumab (P< 0.05).

Table.  Radiographic progression at Week 24 by treatment group

Week 24

(Mean change from baseline)


Secukinumab

10 mg/kg IV → 75 mg SC

n = 202


Secukinumab

10 mg/kg IV → 150 mg SC

n = 202

PBO

n = 202

mTSS

0.02†

0.13†

0.57

Erosion score

0.08†

0.04ǂ

0.35

JSN score

–0.06†

0.10

0.23

TNF-naïve/IR

n = 142/n = 60

n = 143/n = 59

n = 143/n = 59

  mTSS

 

–0.06†/0.21

 

0.15/0.10†

 

0.57/0.58

 

  Erosion score

 

0/0.25

 

0.02/0.08ǂ

 

0.29/0.50

 

  JSN score

 

–0.06†/–0.05

 

0.13/0.02

 

0.28/0.09

 

Concomitant MTX use, yes/no

n = 122/n = 80

n = 121/n = 81

n = 125/n = 77

  mTSS

 

–0.07†/0.14

 

0.14/0.12

 

0.57/0.58

 

  Erosion score

 

0.01†/0.17

 

0.04†/0.02

 

0.34/0.37

 

 JSN score

 

–0.08/–0.03

 

0.10/0.10

 

0.24/0.21

 

†P < 0.05 vs. placebo; ǂP < 0.01 vs. placebo

JSN, joint space narrowing; mTSS, modified total Sharp score; MTX, methotrexate; TNF-naïve/IR, tumor necrosis factor inhibitor naïve/inadequate responder

P-values based on a non-parametric ANCOVA model.

 Conclusion

In patients with active PsA, secukinumab significantly inhibited radiographic progression at 24 wks regardless of prior TNF inhibitor therapy status or concomitant MTX administration; inhibition was sustained through Wk 52.


Disclosure:

D. van der Heijde,

Consulting fees from AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli-Lilly, Galapagos, GSK, Janssen Biologics, Merck, Novartis, Novo-Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, Vertex. ,

5,

Director of Imaging Rheumatology bv,

9,

Rsearch grants from AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli-Lilly, Galapagos, GSK, Janssen Biologics, Merck, Novartis, Novo-Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, Vertex. ,

2;

R. B. M. Landewé,

Consulting fees from Abbott/AbbVie, Ablynx, Amgen, Astra-Zeneca, Bristol-Myers Squibb, Centocor, GlaxoSmithKline, Novartis, Merck, Pfizer, Roche, Schering-Plough, UCB, and Wyeth,

5,

Research grants: Abbott, Amgen, Centocor, Novartis, Pfizer, Roche, Schering-Plough, UCB, and Wyeth,

2,

Speaker fees: Abbott, Amgen, Bristol-Myers Squibb, Centocor, Merck, Pfizer, Roche, Schering-Plough, UCB, and Wyeth,

8,

Director of Rheumatology Consultancy BV, which is a registered company under Dutch law,

9,

Participation in advisory boards: Abbott/AbbVie, Ablynx, Amgen, Astra-Zeneca, Bristol-Myers Squibb, Centocor, GlaxoSmithKline, Novartis, Merck, Pfizer, Roche, Schering-Plough, UCB, Wyeth. ,

9;

P. J. Mease,

Research grants from AbbVie, Amgen, Biogen Idec, BMS, Celgene, Crescendo, Janssen, Lilly, Merck, Novartis, Pfizer, UCB, and Vertex,

2,

Consulting fees from AbbVie, Amgen, Biogen Idec, BMS, Celgene, Covagen, Crescendo, Janssen, Lilly, Merck, Novartis, Pfizer, UCB, and Vertex,

5,

Speakers’ bureau for AbbVie, Amgen, Biogen Idec, BMS, Crescendo, Janssen, Lilly, Pfizer, and UCB,

8;

I. B. McInnes,

Consulting fees from Novartis, Amgen, Janssen, BMS, Pfizer, UCB, Abbvie, Celgene and Lilly,

5;

P. G. Conaghan,

Consulting fees from AbbVie, Janssen, Novartis, Pfizer and Roche,

5,

Speakers’ bureau for Abbvie, Merck, Pfizer, Roche and UCB,

8;

L. Pricop,

Novartis stock ,

1,

Employee of Novartis,

3;

G. Ligozio,

Novartis stock ,

1,

Employee of Novartis,

3;

H. Richards,

Employee of Novartis,

3;

S. Mpofu,

Novartis stock ,

1,

Employee of Novartis,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/secukinumab-a-monoclonal-antibody-to-interleukin-17a-provides-significant-and-sustained-inhibition-of-joint-structural-damage-in-active-psoriatic-arthritis-regardless-of-prior-tnf-inhibitors-or-conc/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology